|Application ||WB, IHC-P, FC, E|
|Calculated MW||50113 Da|
|Other Names||Equilibrative nucleoside transporter 2, 36 kDa nucleolar protein HNP36, Delayed-early response protein 12, Equilibrative nitrobenzylmercaptopurine riboside-insensitive nucleoside transporter, Equilibrative NBMPR-insensitive nucleoside transporter, Hydrophobic nucleolar protein, 36 kDa, Nucleoside transporter, ei-type, Solute carrier family 29 member 2, SLC29A2, DER12, ENT2, HNP36|
|Target/Specificity||This SLC29A2 antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 1-31 amino acids from human SLC29A2.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||SLC29A2 Antibody (N-Term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Synonyms||DER12, ENT2, HNP36|
|Function||Mediates equilibrative transport of purine, pyrimidine nucleosides and the purine base hypoxanthine. Very less sensitive than SLC29A1 to inhibition by nitrobenzylthioinosine (NBMPR), dipyridamole, dilazep and draflazine.|
|Cellular Location||Basolateral cell membrane; Multi-pass membrane protein. Nucleus membrane; Multi-pass membrane protein. Note=Localized at the basolateral cell membrane in polarized MDCK cells|
|Tissue Location||Expressed in skeletal muscle, liver, lung, placenta, brain, heart, kidney and ovarian tissues|
Provided below are standard protocols that you may find useful for product applications.
Mediates equilibrative transport of purine, pyrimidine nucleosides and the purine base hypoxanthine. Very less sensitive than SLC29A1 to inhibition by nitrobenzylthioinosine (NBMPR), dipyridamole, dilazep and draflazine.
Williams J.B.,et al.Biochem. Biophys. Res. Commun. 213:325-333(1995).
Griffiths M.,et al.Biochem. J. 328:739-743(1997).
Crawford C.R.,et al.J. Biol. Chem. 273:5288-5293(1998).
Mangravite L.M.,et al.Am. J. Physiol. 284:F902-F910(2003).
Ota T.,et al.Nat. Genet. 36:40-45(2004).